SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Donald Trump's highly anticipated State of the Union address is driving significant speculative interest and intense political debate around DJT, with the community focused on his economic claims, character, and the broader political divide, anticipating increased volatility for the stock.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending strongly as the market anticipates its upcoming earnings, with community sentiment driven by recent strategic acquisitions in the AI/HPC data center space and bullish remarks from a political figure about data centers needing their own power. High short interest further fuels speculation of a potential squeeze as the company solidifies its position as a key digital infrastructure provider.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is trending following a significant earnings beat and strong forward guidance, with the community celebrating its robust performance and discussing potential short squeezes. Investors are highlighting its profitable compounding and defensible position as an integrated hardware and software public safety technology leader, distinguishing it from broader software market fatigue.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is experiencing significant volatility after receiving an FDA Complete Response Letter for its relacorilant hypercortisolism application, questioning efficacy and leading to a sharp stock decline. While some investors express concern over potential revenue erosion from generic competition and a lengthy path for relacorilant, others view the pullback as an opportunity, emphasizing the company's existing profitable drug, strong cash position, and promising oncology pipeline assets, particularly relacorilant's positive Phase 3 data for ovarian cancer.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

Recent record-breaking battery swap milestones are fueling intense discussion around NIO, with bulls touting the unique Battery-as-a-Service model as a game-changer for profitability and a potential short squeeze, while bears continue to dismiss it as a 'cash burn' and 'bull trap' amid ongoing price volatility.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros Discovery is trending as its board acknowledged Paramount Skydance's revised $31 per share cash offer, which includes a ticking fee and enhanced termination fees, could be a superior proposal to Netflix's current bid. The community is actively discussing the financial certainty and regulatory risks associated with both offers, reflecting the ongoing intensity of this acquisition battle.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is a top trending stock ahead of its crucial earnings report, where high expectations for AI sector growth collide with market concerns over increasing competition and the impact of ongoing geopolitical factors on China sales. Community discussion heavily revolves around the potential for a "blowout" quarter versus predictions of post-earnings price volatility, reflecting the market's dependence on its performance.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a sharp decline driven by concerns that Anthropic's AI tool for COBOL modernization could disrupt its core legacy software and consulting revenues. Despite these fears, a strong counter-narrative suggests the market has overreacted, emphasizing IBM's robust AI strategy, ongoing partnerships, and resilient mainframe business.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

NVAX is highly discussed ahead of its upcoming earnings call, with the community focused on potential strategic partnerships for its Matrix-M adjuvant in oncology and C. difficile, alongside intense speculation about a short squeeze given high institutional ownership and significant short interest. Investors are also actively debating management's effectiveness in capitalizing on the company's valuable pipeline amidst a changing vaccine landscape.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is rallying following its Q4 earnings, which showed revenue growth and strong restaurant expansion, although community discussion is split over its high valuation, tempered same-store sales growth, and comparisons to Chipotle's financial metrics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Equity

This account has been verified as an official NVNO representative.

Verified Account

enVVeno Medical

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

enVVeno Medical Corporation

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

NVNO
enVVeno Medical Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVNO News

NVNOenVVeno Medical Corporation